scholarly journals Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

2009 ◽  
Vol 19 (3) ◽  
pp. 215-226 ◽  
Author(s):  
Floyd R. Sallee ◽  
Andrew Lyne ◽  
Timothy Wigal ◽  
James J. McGough
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Children And Adolescents ◽  
Attention Deficit ◽  
Extended Release ◽  
Safety And Efficacy ◽  
Hyperactivity Disorder

scholarly journals Correction to: Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Akira Iwanami ◽  
Kazuhiko Saito ◽  
Masakazu Fujiwara ◽  
Daiki Okutsu ◽  
Hironobu Ichikawa
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Attention Deficit ◽  
Extended Release ◽  
Extension Study ◽  
Open Label ◽  
Phase 3 ◽  
Safety And Efficacy ◽  
Hyperactivity Disorder

An amendment to this paper has been published and can be accessed via the original article.

scholarly journals Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Akira Iwanami ◽  
Kazuhiko Saito ◽  
Masakazu Fujiwara ◽  
Daiki Okutsu ◽  
Hironobu Ichikawa
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Executive Functioning ◽  
Outcome Measures ◽  
Attention Deficit ◽  
Extended Release ◽  
Open Label ◽  
Phase 3 ◽  
Safety And Efficacy ◽  
Hyperactivity Disorder

Abstract Background To assess the safety and efficacy of long-term administration of guanfacine extended-release (GXR) in adults with attention-deficit/hyperactivity disorder (ADHD). Methods In this open-label, long-term, phase 3 extension study in Japan, 150 patients transitioned from a double-blind trial, and 41 newly enrolled patients received once daily GXR (starting dose 2 mg/day, maintenance dose 4–6 mg/day) for 50 weeks. Primary outcome measures were the frequency and nature of treatment-emergent adverse events (TEAEs); secondary outcome measures included the change from week 0 in ADHD Rating Scale IV with Adult Prompts (ADHD-RS-IV; Japanese version) total and subscale scores, Conners’ Adult ADHD Rating Scales (CAARS), Clinical Global Impression-Improvement (CGI-I) and Patient Global Impression-Improvement (PGI-I) scales, and quality of life (QoL) and executive functioning measures. Results Of all patients, 94.2% (180/191) reported ≥1 TEAE and 19.9% (38/191) discontinued because of a TEAE. Most TEAEs were mild to moderate in severity; there were two serious TEAEs and no deaths. Commonly reported TEAEs (≥10% of patients) were somnolence, thirst, nasopharyngitis, decreased blood pressure, postural dizziness, bradycardia, malaise, constipation, and dizziness. Mean changes from week 0 in ADHD-RS-IV total and subscale scores and CAARS subscale scores were significantly improved in former placebo or GXR patients and new patients at last observation (p < .0001), and the percentage of patients with very much or much improved CGI-I and PGI-I scores increased. Conclusions There were no major safety concerns during long-term GXR administration in adults with ADHD. After long-term treatment, patients had significant improvements from baseline in ADHD symptoms, QoL, and executive functioning. Trial registration Japan Primary Registries Network (https://rctportal.niph.go.jp/en/): JapicCTI-163232, registered 04/21/2016.

Sign in / Sign up

Export Citation Format

Share Document